Prevention and early detection of prostate cancer Journal Article


Authors: Cuzick, J.; Thorat, M. A.; Andriole, G.; Brawley, O. W.; Brown, P. H.; Culig, Z.; Eeles, R. A.; Ford, L. G.; Hamdy, F. C.; Holmberg, L.; Ilic, D.; Key, T. J.; Vecchia, C. L.; Lilja, H.; Marberger, M.; Meyskens, F. L.; Minasian, L. M.; Parker, C.; Parnes, H. L.; Perner, S.; Rittenhouse, H.; Schalken, J.; Schmid, H. P.; Schmitz-Dräger, B. J.; Schröder, F. H.; Stenzl, A.; Tombal, B.; Wilt, T. J.; Wolk, A.
Article Title: Prevention and early detection of prostate cancer
Abstract: Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer. Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but changes in the PSA threshold, frequency of screening, and the use of other biomarkers have the potential to minimise the overdiagnosis associated with PSA screening. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment. Several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer. In this Review, we discuss the present evidence and research questions regarding prevention, early detection of prostate cancer, and management of men either at high risk of prostate cancer or diagnosed with low-grade prostate cancer.
Keywords: immunohistochemistry; survival rate; overall survival; review; cancer risk; prostate specific antigen; protein blood level; cell cycle progression; cancer prevention; genetic association; body weight; cancer screening; smoking cessation; risk assessment; prostate cancer; gleason score; oncogene; diet; fluorescence in situ hybridization; early diagnosis; acetylsalicylic acid; eflornithine; family history; antigen detection; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; finasteride; kallikrein; lycopene; physical activity; high risk population; somatomedin c; dutasteride; lifestyle modification; cyclin d1; steroid 5alpha reductase inhibitor; smad4 protein; osteopontin; sulforaphane; human
Journal Title: Lancet Oncology
Volume: 15
Issue: 11
ISSN: 1470-2045
Publisher: Elsevier Science, Inc.  
Date Published: 2014-10-01
Start Page: e484
End Page: e492
Language: English
DOI: 10.1016/s1470-2045(14)70211-6
PROVIDER: scopus
PMCID: PMC4203149
PUBMED: 25281467
DOI/URL:
Notes: Export Date: 1 December 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Hans Gosta Lilja
    343 Lilja